Analysts’ Top Healthcare Picks: Ikena Oncology (IKNA), PMV Pharmaceuticals (PMVP)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 07 2025
0mins
Source: Business Insider
Ikena Oncology (IKNA): Analyst Matt Phipps from William Blair maintains a Buy rating on Ikena Oncology, which has a Moderate Buy consensus among analysts, despite Phipps' average return being -10.4%.
PMV Pharmaceuticals (PMVP): Analyst Yaron Werber from TD Cowen also holds a Buy rating for PMV Pharmaceuticals, which is near its 52-week low, and has a Moderate Buy consensus with an average return of 8.2%.
Analyst Views on PMVP
Wall Street analysts forecast PMVP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMVP is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.140
Low
5.00
Averages
5.00
High
5.00
Current: 1.140
Low
5.00
Averages
5.00
High
5.00
About PMVP
PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. In addition to its rezatapopt program, it is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets. These programs have been developed using its precision oncology platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
